Frank Rimerman Advisors LLC Has $375,000 Stock Holdings in Humana Inc. (NYSE:HUM)

Frank Rimerman Advisors LLC grew its holdings in Humana Inc. (NYSE:HUM) by 37.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,478 shares of the insurance provider’s stock after purchasing an additional 402 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Humana were worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Pinnacle Wealth Management Advisory Group LLC lifted its stake in shares of Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares during the period. Atlas Brown Inc. increased its position in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares in the last quarter. Moors & Cabot Inc. increased its position in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares in the last quarter. Mather Group LLC. increased its position in Humana by 21.0% in the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after buying an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its position in Humana by 26.1% in the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after buying an additional 43 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.32% of the stock is owned by company insiders.

Humana Stock Performance

HUM stock opened at $253.11 on Monday. The firm has a market cap of $30.55 billion, a PE ratio of 25.44, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a 50 day moving average of $271.37 and a 200-day moving average of $279.50. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.40%. Humana’s payout ratio is 35.58%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HUM. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Truist Financial boosted their target price on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Morgan Stanley decreased their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.